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Abstract Discoidin death receptor 2 (DDR2) receptor
belongs to a DDR family that shows a tyrosine kinase
activity. The somatic mutations in DDR2 gene, reported in
non-small cell lung cancer (NSCLC), are involved in up-
regulation of cells’ migration, proliferation and survival.
A S768R substitution in DDR2 gene was commonly
reported in squamous cell lung carcinoma. Clinical data of
patients carrying the DDR2 gene mutation suggest that its
presence can be independent of gender and age. The
effectiveness of an oral dual-specific (Src and Abl) multi-
kinase inhibitors—dasatinib—was observed in different
cell lines and in some NSCLC patients with identified
DDR2 mutation. In the present study, we have used three
molecular methods (ASP-real-time PCR, ASP-DNA-FLA
PCR and direct sequencing) to detect the DDR2 gene
mutation in 143 patients with NSCLC metastases to the
central nervous system (CNS). The prevalence of the
DDR2 gene mutation was correlated with the occurrence of
mutations in the EGFR, KRAS, HER2 and BRAF genes. We
identified three patients (2.1 % of studied group) with
DDR2 mutation. The mutation was observed in two
patients with low differentiated squamous cell lung cancer
and in one patient with adeno-squamous cell carcinoma
(ADSCC). In ADSCC patients, DDR2 mutation coexisted
with G12C substitution in KRAS gene. According to the
current knowledge, examination of the presence of the
DDR2 gene mutation in metastatic lesion is the first such
report worldwide. The information, that these driver
mutations are present in CNS metastases of NSCLC, could
broaden therapeutic choices in such group of patients.
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Abbreviations
ADSCC Adeno-squamous cell carcinoma
ASP-PCR Allele-specific polymerase chain reaction
CNS Central nervous system
DDR2 Discoidin death receptor 2
FFPE Formalin-fixed paraffin-embedded
FLA Fragment length analysis
NSCLC Non-small cell lung cancer
SCC Squamous cell lung carcinoma
M. Nicos´ (&)  T. Powro´zek  P. Krawczyk  J. Milanowski
Department of Pneumonology, Oncology and Allergology,




Postgraduate School of Molecular Medicine, Medical University
of Warsaw, 02-091 Warsaw, Poland
B. Jarosz  T. Trojanowski
Pathological Laboratory, Department of Neurosurgery and
Pediatric Neurosurgery, Medical University of Lublin,
20-954 Lublin, Poland
B. Paja˛k  K. Kucharczyk
BioVectis Ltd, Kucharczyk TE, 02-106 Warsaw, Poland
B. Paja˛k
Electron Microscopy Platform, Mossakowski Medical Research
Centre, Polish Academy of Sciences, 02-106 Warsaw, Poland
M. Sawicki
Department of Thoracic Surgery, Medical University of Lublin,
20-954 Lublin, Poland
J. Milanowski
Institute of Agricultural Medicine, 20-090 Lublin, Poland
123
Med Oncol (2014) 31:176
DOI 10.1007/s12032-014-0176-4
Introduction
Discoidin death receptor 2 (DDR2) receptor belongs to a
DDR family that shows tyrosine kinase activity. A collagen
is needed to stimulate phosphorylation of the DDR2
receptor that promotes cell migration, proliferation and
survival. Apart from its important role in development and
tissue repair, the DDR2 also regulates primary and meta-
static cancer progression by down-streaming of the DDR2
signaling pathways including Shp-2, Src, STAT and
MAPK. Rare frequency of the DDR2 gene mutations has
been reported in kidney, breast, brain, endometrial and
colon cancers [1, 2]. However, a substitution of serine to
arginine at position 768 in exon 18 of the DDR2 (S768R)
gene has been most commonly described (2.2–3.8 %) in
squamous cell lung carcinoma (SCC) patients and in
smokers. No alterations in the DDR2 gene copy number or
protein over-expression were reported [3, 4].
The clinical data of patients with DDR2 gene mutation
suggest that its presence is independent of gender and age.
A functional characteristic has showed that cells carrying
this mutation are sensitive to an oral dual-specific (Src and
Abl) multikinase inhibitors (dasatinib, imatinib, nilotinib,
ponatinib, sorafenib and pazopanib) [2, 4]. It also had been
previously mentioned that dasatinib inhibited lung cancer
cell lines with DDR2 mutation [5, 6]. A phase II trial
(NCT00787267) determined the dasatinib activity in pre-
viously treated patients with advanced non-small cell lung
cancer (NSCLC). However, another phase II study
(NCT01514864) recruited only SCC patients with DDR2
mutation and indicated satisfactory results of the dasatinib
as first- or subsequent-line therapy in this group of patient
[4, 5, 7].
In the future, the presence of the DDR2 gene mutation
may become a potential predictive marker for the effec-
tiveness of molecularly targeted therapies in SCC patients
group. However, there is no evidence on the prevalence of
the DDR2 gene mutations in a metastatic NSCLC. Taking
into account that the central nervous system (CNS) is one
of the most frequent location for metastases of NSCLC, the
aim of the study was to estimate the presence of the S768R
substitution in the DDR2 gene in tissue samples from
Caucasian patients with the CNS metastases of NSCLC.
Materials and methods
Patients and material
A total of 143 Caucasian patients with NSCLC metastatic
lesions in the CNS were enrolled in present retrospective
study. The corresponding primary NSCLC tumors were
simultaneously available from 30 patients. The patients
underwent routine neurosurgical procedures with a pallia-
tive aim, and the median survival time from lung cancer
diagnosis to death was 9.2 months. Moreover, none of
patients was treated with chemotherapy, radiotherapy or
molecularly targeted therapies. Detailed characteristic of
studied group has been presented in Table 1.
The study was approved by the Ethics Committee of the
Medical University of Lublin, Poland (No. KE-0254/86/
2013).
Mutation analysis
DNA was isolated from formalin-fixed paraffin-embedded
(FFPE) metastatic tissue samples using QIAamp DNA
FFPE tissue kit (Qiagen, USA) according to a manufac-
turer’s protocol. Estimation of the S768R mutation in the
DDR2 gene was conducted using three methods based on a
PCR: the allele-specific real-time PCR (ASP-real-time
PCR), the allele-specific PCR with DNA fragment length
analysis (ASP-DNA-FLA PCR) and the direct sequencing.
Additionally, the incidence of mutation in EGFR (deletions
in exon 19 and substitutions: L858R, T790M, L861Q,
S768I, G719X), HER2 (A775YVMA or M774AYMVM
insertion), KRAS (codon 12, 13 and 61) and BRAF (V600E
substitution) genes also was assessed in the analyzed
material.
ASP-real-time PCR method
The S768R substitution was analyzed using the real-time
PCR method with DNA intercalating dye and the allele-
specific primers for mutated (mt) and wild-type (wt) DDR2
gene. Total volume of PCR mixture (15 ll) contains: 8 ll
of Master Mix (PrimerDesign Ltd, UK) with DNA inter-
calating dye (ChromofyTM), 1 ll of purified genomic DNA
(20 ng/ll), 2 ll of each primers for mt or wt DDR2 gene
and 4 ll of nuclease-free water. The amplification of
examined region was performed in 48-well plates using the
Eco real-time PCR device (Illumina, USA) in following
steps: pre-denaturation 95 C-10 min and 35 cycles in
conditions: 95 C-15 s and 62 C-60 s. The codon 768 of
DDR2 gene was tested simultaneously in each sample for
mt and wt form in the same PCR. The negative control of
the ASP-real-time PCR was the reaction with DNA isolated
from peripheral blood leukocytes of healthy individual.
Samples were assessed as positive if amplification in the
real-time PCR was observed both for mutant and for wild
type of DDR2 gene. The samples with late amplification
(Ct [ 32 cycle) of wt region of codon 768 were excluded
from analysis, and samples with late amplification (Ct [ 32
cycle) of mt region of DDR2 gene were assessed as
negative.
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ASP-DNA-FLA PCR analysis
The S768R substitution was analyzed using a PCR with the
allele-specific primers. Sequences of primers were the
same as in the real-time PCR, but one of the primers was
labeled by fluorochrome Cy5. The PCR mixture contained:
10 ll of Master Mix (Thermo Scientific, USA), 1 ll of
purified genomic DNA (20 ng/ll), 2 ll of each primers for
mt or wt of DDR2 and nuclease-free water up to 20 ll of
total volume. PCR was performed in TPersonal thermo-
cycler (Biometra, Germany) in following steps: pre-dena-
turation (95 C-10 min), 35 cycles (95 C-30 s, 64 C-40 s
and 72 C-45 s) and ended elongation (72 C-10 min). The
length analysis of the amplified DNA fragments in poly-
acrylamide gel (DNA-FLA) was conducted in ALF
Express II sequencer using ALFwin Fragment Analyzer
(Amersham Pharmacia Biotech, Sweden). The product of
amplification was observed in length of 129 bp. DNA
isolated from peripheral blood leukocytes of healthy indi-
vidual was used as a negative control. The samples were
assessed as positive if amplification was observed as peaks
both for mt and for wt of the DDR2 gene in ALFwin
Software. The samples with a low fluorescence level
(RFU \ 10) for wild type of codon 768 were excluded
from analysis and were repeated in next PCR. The samples
with a low fluorescence level (RFU \ 10) for mutated
codon 768 were assessed as wild type.
Direct sequencing
The Sanger cycle sequencing reactions were performed in
separate vials for each dideoxynucleotide. 100 lg of the
PCR products were purified with ExoSap enzyme mix
(according to the manufacturer’s instructions) and used as
template. The sequencing was carried out with Big Dye
Terminator v3.1 Cycle Sequencing RR-2500 according to
the manufactures instructions. The cycle sequencing con-
ditions for the PCR product as template were as follows:
95 C for 10 s, 52 C for 5 s and 60 C for 3 min for 75
cycles.
Calculation of mutated DNA content in examined
samples and statistical analysis
During the next part of the study, we used mathematical
formula to estimate the percentage content of mt DNA in
the samples with detected mutation. The mutation level for
amplified region was determined according to the follow-
ing equation:
% mutated DNA ¼ 2DCt  100%
DCt (analyzed sample) = the average Ct value from the
mutant reaction - the average Ct value from the wild-type
reaction.
The data were present as a frequency of DDR2 gene
mutation in analyzed group and subgroup of patients.
Results
Based on the real-time PCR results, the presence of
amplified region for the S768R substitution in the DDR2
gene was revealed (mean Ct = 25th cycle) in four patients
(5.6 % of evaluated group, Fig. 1) with the CNS metasta-
ses of NSCLC. In each case, the amplification of wt control
also was also observed (mean Ct = 20th cycle), as well as
the presence of mt amplification in negative control was
Fig. 1 Amplification curves of DDR2 gene in ASP-real-time PCR
analysis. Curve 1 represents amplification of wt DDR2 region and
curve 2 amplification of product for mt DDR2 region in the same
patient. Curve 3 represents negative control of reaction
Table 1 Characteristic of studied group
Gender
Male, n (%) 99 (69.2)
Female, n (%) 44 (30.8)
Age
Median age ± SD (years) 60 ± 8.8
C60 years, n (%) 71 (49.7)
\60 years, n (%) 72 (50.3)
Pathomorphological diagnosis
Adenocarcinoma, n (%) 61 (42.7)
Squamous cell carcinoma, n (%) 23 (16.1)
NSCLC-NOS, n (%) 38 (26.6)
Large cell carcinoma, n (%) 21 (14.6)
Smoking status
Smokers, n (%) 86 (60.1)
Non-smokers, n (%) 32 (22.4)
Lack of data, n (%) 25 (17.5)
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not shown. In patients with the DDR2 mutations, corre-
sponding primary tumor was not available.
In second part of the study, all the real-time PCR
positive samples were tested for the S768R substitution in
ASP-DNA-FLA PCR and in the direct sequencing. How-
ever, only in three samples, the product of amplification
(Fig. 2b) was observed during the ASP-DNA-FLA PCR
assay. The product of amplification was observed in
patients with 7.5–9 % of mutated DNA. However, the
ASP-DNA-FLA PCR was negative in one patient with low
content of mutated DNA (\4 %). Therefore, there is a
probability that in this case the result of the real-time PCR
was false-positive caused by nonspecific binding of primers
or the sensitivity of ASP-DNA-FLA PCR was too low.
Unfortunately, the direct sequencing only showed the
presence of wt DDR2 gene in all analyzed samples.
However, based on mathematical analysis, the content of
mt DNA in all positive samples was assessed as \10 %
(Table 2), making it impossible to obtain reliable results in
direct sequencing method. Moreover, the low quality of
DNA isolated from FFPE tissue samples and sub-clonality
of DDR2 mutations in the metastases could have affected
on the results of direct sequencing analysis. All three
methods have different sensitivity of mt DNA detection
that had been previously described (direct sequencing
[40 %, real-time PCR[1 %, ASP-DNA-FLA PCR[5 %)
[8–10]. Taking into account a low purity of the analyzed
samples, the next generation sequencing method had not
been used to verify positive results.
According to real-time PCR and ASP-PCR-DNA-FLA
analysis, we detected 3 patients (2.1 % of evaluated group)
with S768R substitution in DDR2 gene. All three DDR2
gene-positive patients were current or former smokers.
Two patients (52-year-old male and 60-year-old female)
were diagnosed SCC (8.7 % of SCC), and their DDR2 gene
mutation was mutually exclusive. Moreover, one 70-year-
old female was diagnosed adeno-squamous cell lung car-
cinoma based on microscopy examination and immuno-
histochemistry (IHC) staining and she also was carrier of
G12C substitution in KRAS gene.
Analysis of EGFR, KRAS, HER2 and BRAF mutations
did not show any coexistence with S768R mutation in
DDR2 gene, besides one mentioned patient.
Additionally, in previous studies, we reported detection
of 9 (6.29 % of studied group) common activating EGFR
gene mutations (6 L858R substitutions and 3 deletion in
exon 19), primary T790 M mutation in 3 (2.1 %) patients,
20 (14 %) KRAS gene mutations (19 in codon 12 and 1 in
codon 61), 1 (0.67 %) insertion in HER2 gene and none
V600E substitution in BRAF gene.
Discussion
Our findings presented in this study have shown that the
S768R substitution in the DDR2 gene is detectable not only
in patients with primary NSCLC but also in metastatic
lesions of lung cancer. According to current knowledge,
Fig. 2 Example of DDR2 gene examination in ASP-PCR-DNA-FLA.
a The presence of DDR2 amplification with primer complementary to
wt of DDR2 gene and lack of DDR2 amplification with a primer
complementary to the mt DDR2 gene. b The presence of DDR2
amplification both with primer complementary to wt and mt DDR2
gene
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our study about the presence of the DDR2 gene mutation in
a metastatic lesion is the first such report worldwide. The
prevalence of these mutations (2.1 %) in the CNS metas-
tases of NSCLC in Caucasian patients is in accordance
with previous studies provided in primary tumors [3, 11,
12]. Moreover, the DDR2 gene mutation is commonly
detected in SCC primary tumors [2, 3, 12]. Two of our
patients were also diagnosed such type of lung cancer.
However, one patient was diagnosed low differentiated
adeno-squamous lung carcinoma and she also was carrying
both of DDR2 and KRAS gene mutations. It is possible that
the DDR2 gene mutation was detected in squamous cell
component of lung cancer and KRAS gene mutation was
detected in adenocarcinoma component of this malignancy.
However, the coexistence between driver mutations was
seldom reported, and microdissection was not performed to
confirm this suspicion [13, 14].
Despite of the low sensitivity, the direct DNA
sequencing is still considered as gold standard for mutation
detection. However, it was indicated that techniques based
on the real-time PCR methodology (for example, PNA-
mediated real-time PCR clamping) are highly sensitive and
allow to detect mutant alleles even at 100-fold lower levels
than wild type [8, 15, 16]. On the other hand, the direct
sequencing allowed to detect two uncommon not activated
mutations. Moreover, several authors suggested that to
improve the sensitivity of molecular analysis all tissue
samples should be evaluated in the microscope by a
pathologist to select an appropriate area with high pro-
portion of tumor cells [8, 16].
For the first time, somatic mutations in DDR1 and
DDR2 genes were reported by the Davis et al. [11] in two
lung cancer patients (one SCC and one large cell carci-
noma) and in one lung cancer cell line (NCI-H1770). On
the other hand, the Ford et al. demonstrated that the
expression of DDRs receptor is significantly deregulated in
NSCLC tumors. Furthermore, the Ford et al. [12] suggested
that the genetic status of DDR1 and DDR2 genes can be an
independent favorable prognostic marker for early stages
of NSCLC.
Hammerman et al. [3] had sequenced 290 SCC tissue
samples and indicated 11 (3.8 %) DDR2 gene mutations
that were found both in the sequence of a kinase domain
and in other regions of this gene. Apart from nine common
S768R substitutions, they identified two rare G774 muta-
tions. Moreover, they found L239R and I638F mutations in
the HCC-366 and NCI-H2286 SCC cell lines, respectively.
The analysis of the DDR2 gene copy number did not reveal
the DDR2 over-expression in tested group. Unfortunately,
clinical data of the patients were limited; therefore, the
presence of DDR2 gene mutation did not show any cor-
relation with age, gender or smoking status.
Johnson et al. [7] on the phase II study demonstrated
clinical activity of the dasatinib in a molecularly unselected
population of patients with NSCLC. However, the response
rate was not favorable in comparison with standard therapy
response rate (43 vs. 40 % of disease control rates). Pro-
gression-free survival of examined patients was
1.36 months in the dasatinib treatment arm and 3.6 months
in control arm. For this reason, they suggested that future
studies of the dasatinib should be based on molecular
predictive factors.
It has been shown that tumor cells with oncogenic
DDR2 gene mutation can be effectively inhibited by
multikinase inhibitors [2, 4, 5, 7]. Hammerman et al. [3]
had reported that the dasatinib showed particular efficiency
against SCC cell lines bearing DDR2 gene mutations. The
dasatinib inhibited proliferation of the DDR2 mutant NCI-
H2286 and HCC-366 cells while the imatinib was less
effective in the same tested cell lines. Moreover, the da-
satinib and the imatinib were less effective against the
A549 cell line, which carries a KRAS mutation and does
not have any DDR2 mutations. On the other hand, the NCI-
H1703 SCC cell line, which contained a PDGFRA ampli-
fication, was sensitive to both drugs.
Pitini et al. [17] presented a case report of 50-year-old
women, all heavy smokers, with coexistence of primary
SCC and chronic myelogenous leukemia that was treated
with the dasatinib. After 10 weeks of the dasatinib therapy,
the patient had normal blood counts and the lung tumor
was nearly completely resolved. Eight months after starting
the treatment, when patients still responded to the dasati-
nib, authors sequenced kinase domain of DDR2 gene and
identified the S768R mutation. This result confirmed the
Table 2 Results of analysis of DDR2 gene according to the type of methods used for detection of DDR2 gene abnormalities






([1 % of mt DNA)
ASP-DNA-FLA PCR
([5 % of mt DNA)
Direct sequencing
([10 % of mt DNA)
1 (9 %) SCC ? ? -
2 (8 %) SCC ? ? -
3 (7.5 %) ADSCC ? ? -
4 (4 %) AC ? - -
Med Oncol (2014) 31:176 Page 5 of 6 176
123
suspicions that the dasatinib can effectively inhibit the
growth of tumor with DDR2 gene mutation.
Based on the overall data, we would like to conclude
that the DDR2 gene mutation is detectable in the CNS
metastases of NSCLC, and analysis of gene profile in
cancer patients may extend the scope of molecularly tar-
geted therapies used both in patients with primary and
metastatic NSCLC. Moreover, in the near future, the per-
sonalized therapy based on the assessment of different gene
mutations in NSCLC patients may become a reality.
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